ArticleDiabetes care2026
Accuracy, Variability, and Bias of Glycemic Biomarkers in Patients Treated With Maintenance Dialysis.
Article in Diabetes care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Correlation Between Glycemic Biomarkers and Continuous Glucose Monitoring Metrics in Chronic Kidney Disease: A Systematic Review and Correlation Meta-Analysis.Journal of clinical medicine · 2026Review
- Glycemic assessment when hemoglobin A1c is unreliable: a clinical-laboratory framework for kidney disease, anemia, and hemoglobinopathies.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectiveAccurate assessment of glycemia in patients treated with maintenance dialysis is imperative and hampered by known biases of glycated hemoglobin (HbA1c) in kidney failure (KF). This study evaluated the accuracy, variability, and covariate bias of three glycemic biomarkers compared with glycemia measured by continuous glucose monitor (CGM) among people with and without diabetes treated with maintenance dialysis. RESEARCH DESIGN AND
methodsIn a prospective community-based cohort study, 251 participants treated with maintenance dialysis wore a Dexcom G6 Pro CGM for 10 days. We compared correlations of HbA1c, glycated albumin (GA), and fructosamine with CGM-derived mean glycemia and examined sources of bias.
resultsParticipants (43% women; 63% with diabetes) had a median of 9.3 (interquartile range 8.5-9.4) valid days of CGM data. Mean (SD) HbA1c, GA, fructosamine, and mean CGM glucose were 6.2% (1.4%), 19.6% (6.3%), 351 (99) µmol/L, and 170 (63) mg/dL, respectively. HbA1c, GA, and fructosamine all strongly correlated with mean CGM blood glucose, with HbA1c and GA more correlated than fructosamine (overall, r = 0.85, r = 0.87, and r = 0.70, respectively; in diabetes, r = 0.84, r = 0.84, and r = 0.64, respectively). Compared with mean CGM glucose, HbA1c was significantly biased by erythropoiesis-stimulating agent dose, BMI, hemoglobin, and serum albumin; GA and fructosamine were biased by dialysis modality and vintage, residual kidney function, and BMI.
conclusionsHbA1c and GA were strongly correlated with mean CGM blood glucose, but all biomarkers had substantial bias by relevant clinical characteristics. HbA1c and GA may be useful assessments of average glycemia in patients treated with maintenance dialysis, if bias can be adequately addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.